Novartis FY2026 EPS Estimate Lowered by Erste Group Bank

Novartis AG (NYSE:NVS) – Investment analysts at Erste Group Bank cut their FY2026 earnings per share (EPS) estimates for Novartis in a research note issued on Thursday, August 27th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $8.95 for the year, down from their prior forecast of $9.01. The consensus estimate for Novartis’ current full-year earnings is $8.84 per share.

A number of other equities analysts have also recently commented on the stock. Citigroup reaffirmed a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $141.20.

Novartis Trading Down 1.0%

Shares of NVS opened at $152.22 on Monday. Novartis has a twelve month low of $121.57 and a twelve month high of $170.46. The company has a market cap of $290.46 billion, a P/E ratio of 22.96, a P/E/G ratio of 2.64 and a beta of 0.45. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The company’s fifty day simple moving average is $155.14 and its 200-day simple moving average is $153.72.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The company had revenue of $14.95 billion during the quarter.

Institutional Trading of Novartis

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Auto Owners Insurance Co grew its holdings in shares of Novartis by 13,687.0% in the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock worth $638,103,000 after purchasing an additional 4,594,726 shares during the last quarter. WCM Investment Management LLC bought a new stake in Novartis during the 1st quarter valued at about $220,004,000. Morgan Stanley boosted its position in Novartis by 14.9% in the 4th quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock valued at $1,223,860,000 after buying an additional 1,148,033 shares during the period. GQG Partners LLC boosted its position in Novartis by 39.6% in the 4th quarter. GQG Partners LLC now owns 3,158,122 shares of the company’s stock valued at $435,414,000 after buying an additional 895,255 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in Novartis in the 4th quarter worth about $108,638,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.